💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Dabigatran

Phase 4 Approuvé Small molecule
Half-Life
12-17 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
471.5 g/mol
LogP
1.7
Phase
4

An anticoagulant that directly inhibits thrombin, a key protein in the blood clotting process. It is used to prevent blood clots and strokes in certain patients.

Masse moléculaire

471,5100 g/mol

LogP

1,70

TPSA

150,00 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Non-Small Cell Lung Cancer Alzheimer's Disease Migraine Melanoma Systemic Lupus Erythematosus Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Type 2 Diabetes Breast Cancer Atopic Dermatitis HIV/AIDS Heart Failure Atrial Fibrillation Prostate Cancer Colorectal Cancer

Classes de médicaments

B — B - Blood and Blood Forming Organs

Mécanisme d'action

Direct thrombin (Factor IIa) inhibitor.

Pharmacokinetics (PK)

Half-Life 12-17 hours

Pharmacodynamics (PD)

Mécanisme

Direct thrombin (Factor IIa) inhibitor.

Structure 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CN1C2=C(C=C(C=C2)C(=O)N(CCC(=O)O)C3=CC=CC=N3)N=C1CNC4=CC=C(C=C4)C(=N)N

                

                

                
                

                    
InChI

                    
InChI=1S/C25H25N7O3/c1-31-20-10-7-17(25(35)32(13-11-23(33)34)21-4-2-3-12-28-21)14-19(20)30-22(31)15-29-18-8-5-16(6-9-18)24(26)27/h2-10,12,14,29H,11,13,15H2,1H3,(H3,26,27)(H,33,34)

                

                

                

                    
                    

                        
Molecular Formula

                        
C25H25N7O3

                    

                    
                    

                        
HBD / HBA

                        
4 / 7

                    

                    
                    

                        
Liaisons Rotatives

                        
9

                    

                    
                    
                    

                        
Atomes Lourds

                        
35

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            F2 (Thrombin)
                            Inhibitor
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            ABCB1 (P-glycoprotein)
                            Substrate
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Major


                            
                                Dabigatran + Ibuprofen
                            
                        

                        
                        
Ibuprofen with dabigatran increases GI bleeding risk through additive effects; dabigatran itself carries a higher inherent GI bleeding risk than other DOACs.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Dabigatran + Diltiazem
                            
                        

                        
                        
Diltiazem increases dabigatran plasma levels through P-glycoprotein inhibition, potentially raising bleeding risk without a change in INR (dabigatran has no INR to monitor).

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Dabigatran + Cyclosporine
                            
                        

                        
                        
Cyclosporine dramatically increases dabigatran exposure through P-gp inhibition, raising the risk of serious or life-threatening bleeding.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Dabigatran + Aspirin
                            
                        

                        
                        
Low-dose aspirin combined with dabigatran increases bleeding risk; clinical evidence suggests a 2-fold increase in major bleeding events.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Foire aux questions

                

                    
                    

                        
                        

                            
An anticoagulant that directly inhibits thrombin, a key protein in the blood clotting process. It is used to prevent blood clots and strokes in certain patients.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Direct thrombin (Factor IIa) inhibitor.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Dabigatran: Half-life: 12-17 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Dabigatran is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Warfarin
                            Small molecule
                        
                        
                        
                            Clopidogrel
                            Small molecule
                        
                        
                        
                            Apixaban
                            Small molecule
                        
                        
                        
                            Rivaroxaban
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 216210.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Avertissement médical

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.